The Registry Study of Genetic Alterations of Melanoma in Taiwan

Launched by NATIONAL HEALTH RESEARCH INSTITUTES, TAIWAN · Apr 23, 2025

Keywords

ClinConnect Summary

This clinical trial, called the Registry Study of Genetic Alterations of Melanoma in Taiwan, is looking into how different types of melanoma, a serious skin cancer, behave in patients from Taiwan. The study focuses on specific types of melanoma that are more common in Asia, like acral lentiginous melanoma and mucosal melanoma, which have different characteristics and treatment responses compared to melanoma seen in Caucasian populations. The goal is to better understand the genetic changes in these tumors and how they affect treatment outcomes, especially since patients in Taiwan may experience higher recurrence rates and lower effectiveness from standard therapies.

To be eligible for this trial, participants must be at least 18 years old and have a confirmed diagnosis of melanoma. There are different groups within the study based on the stage of melanoma, ranging from early-stage to advanced cases. Patients will need to provide tumor samples for genetic testing and agree to follow-up appointments. This study is currently recruiting participants, and all genders are welcome. It’s important for potential participants to fully understand the study and be willing to cooperate throughout the research process.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age \> 18 years old
• • 2. Pathologically confirmed melanoma. (Patients with additional malignancies requiring treatment or follow-up are allowed. Only treatment for melanoma should be recorded).
• • 3. ECOG performance status \< 3
• • 4. Cohort 1(early acral melanoma): melanoma, stage I/II; Cohort 2 (locally advanced acral melanoma): melanoma, stage III, resectable; and Cohort 3 (advanced): unresectable / metastatic melanoma, stage III/IV or recurrent melanoma (unresectable). Staging is based on AJCC Cancer Staging System 8th edition). The patients with advanced melanoma with available comprehensive NGS report are included in cohort 4.
• • 5. Willingness to provide archival or newly obtained tumor tissues for this study proposal
• • 6. Life expectancy more than 3 months -
• • 7. Patients fully understand the protocol with the willingness to have regular follow-up
• Exclusion Criteria:
• • 1. Inability to cooperate by providing a complete medical history
• • 2. No available tumor tissues for genetic testing (archived tissue sampling more than 5 years from screening date)
• • 3. Undesirable compliance (Mental status is not fit for further treatment or data collection.)